Literature DB >> 30753424

Asbestosis and silicosis hospitalizations in Italy (2001-2015): results from the National Hospital Discharge Registry.

Pierpaolo Ferrante1.   

Abstract

BACKGROUND: This work is aimed at evaluating the quality of Italian hospitalizations data about asbestosis and silicosis, assessing the impact of these diseases on the national health system and providing advice related to public health.
METHODS: Italian hospital discharge data (2001-15) with diagnosis of asbestosis or silicosis were analysed by the multiple correspondence analysis and diseases epidemics were evaluated through hospitalization rates.
RESULTS: Hospitalizations were concentrated in the northwestern area, referred mainly to males and oldest people, the most treated tumors were lung cancer and mesothelioma (for asbestosis) and cares were aimed at reducing symptoms and increasing blood oxygenation. Overall adjusted Italian hospitalization rates of asbestosis and silicosis were, respectively, 25.2 and 74.9 per 1 000 000 residents. With respect to asbestosis, hospitalizations treating silicosis reported doubled mortality (10.5 vs. 5.7%), longer stays (10.4 vs. 8.6 mean days) and older patients (77 vs. 72 years on average). Diseases rates reduced over time (with a steeper slope for silicosis) and in both fibroses increased hospital mortality (92.1% in asbestoses, 59.5% in silicoses) and percentage of urgent hospitalizations (116.0% in asbestoses, 56.6% in silicoses).
CONCLUSION: Hospitalizations data regarding asbestosis and silicosis are consistent. Silicosis had a higher impact than asbestosis on the Italian health system. Although data show decreasing incidence of both fibroses, multiple correspondence analysis highlights that levels of illness severity were higher in silicosis and increased over time in both diseases. Further studies investigating the effectiveness of the current health surveillance programs concerning these diseases are suggested.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.

Entities:  

Year:  2019        PMID: 30753424     DOI: 10.1093/eurpub/ckz003

Source DB:  PubMed          Journal:  Eur J Public Health        ISSN: 1101-1262            Impact factor:   3.367


  3 in total

1.  Astragaloside IV alleviates silica‑induced pulmonary fibrosis via inactivation of the TGF‑β1/Smad2/3 signaling pathway.

Authors:  Nannan Li; Ke Wu; Feifei Feng; Lin Wang; Xiang Zhou; Wei Wang
Journal:  Int J Mol Med       Date:  2021-01-15       Impact factor: 4.101

2.  The Protective Role of Tanshinone IIA in Silicosis Rat Model via TGF-β1/Smad Signaling Suppression, NOX4 Inhibition and Nrf2/ARE Signaling Activation.

Authors:  Feifei Feng; Peng Cheng; Huanan Zhang; Nannan Li; Yuxin Qi; Hui Wang; Yongbin Wang; Wei Wang
Journal:  Drug Des Devel Ther       Date:  2019-12-18       Impact factor: 4.162

3.  Genotoxicity Response of Fibroblast Cells and Human Epithelial Adenocarcinoma In Vitro Model Exposed to Bare and Ozone-Treated Silica Microparticles.

Authors:  Sabrina Colafarina; Piero Di Carlo; Osvaldo Zarivi; Massimo Aloisi; Alessandra Di Serafino; Eleonora Aruffo; Lorenzo Arrizza; Tania Limongi; Anna Poma
Journal:  Cells       Date:  2022-01-11       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.